After pandemic delays, FDA still struggling to inspect foreign drug manufacturers

In the wake of recent deaths from bacteria-tainted eyedrops, a ProPublica analysis of FDA data reveals that the agency inspected only 6% of the overseas plants where drugs and their ingredients are produced in 2022.